Plain-English translation of NCT07387471 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an oral medication, to see how well it works for people with Waldenström macroglobulinemia or lymphoplasmacytic lymphoma—rare types of blood cancers—that have come back or stopped responding to previous treatments. The study will measure changes in disease activity and safety over about 28 months. About 14 adults in Japan will participate across 20 study sites.
This medication has shown promise in treating these rare blood cancers, but more research is needed to understand how well it works for Japanese patients specifically and to confirm it is safe and effective for people whose cancer has returned or become resistant to other treatments.
You will take the medication by mouth, starting at a lower dose that gradually increases to a target dose over the study period of about 28 months. You will attend regular visits at a hospital or clinic for check-ups, blood tests, and scans to monitor how the treatment is working and to watch for any side effects. The study involves more frequent visits and monitoring than some standard treatments, but your medical team will be watching closely to keep you safe.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Japan